Lipo‐Glc‐1,6‐ <scp> P <sub>2</sub> </scp> : A Bioprecursor Prodrug for Phosphomannomutase‐2 Congenital Disorder of Glycosylation
, a novel prodrug with good stability and oral bioavailability. Its advantageous physicochemical profile was confirmed through metabolomics-based studies in fibroblasts derived from PMM2-CDG patient.
Authors
- Bruno Hay Mele (ORCID: https://orcid.org/0000-0001-5579-183X)
- Loretta Lazzarato (ORCID: https://orcid.org/0000-0001-7100-8593)
- Maria Vittoria Cubellis (ORCID: https://orcid.org/0000-0001-6147-6553)
- Barbara Rolando (ORCID: https://orcid.org/0000-0001-6138-1503)
- Debora Paris (ORCID: https://orcid.org/0000-0003-4526-8353)
- Giuseppina Andreotti (ORCID: https://orcid.org/0000-0002-1594-0156)
- Maria Grazia Rimoli (ORCID: https://orcid.org/0000-0002-6015-3741)
- Federica Sodano (ORCID: https://orcid.org/0000-0003-2013-4893)
- Vincenza Andrisano (ORCID: https://orcid.org/0000-0003-4396-1904)
- Maria Monticelli (ORCID: https://orcid.org/0000-0003-3136-2138)
- Angela De Simone
Institutions
- San Raffaele University of Rome (IT)
- Federico II University Hospital (IT)
- National Research Council (IT)
- University of Turin (IT)
- University of Naples Federico II (IT)
- University of Bologna (IT)
Publication Details
- Journal
- IUBMB Life
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1002/iub.70101
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Regione Campania
- Ministero dell'Università e della Ricerca